- ASSISTANT PROFESSOR Medicine, Liver Diseases
Postdoc, Broad Institute of MIT and Harvard
M.D., University of Tsukuba
Ph.D., University of Tokyo
Hoshida laboratoryHoshida lab employs multidisciplinary, translational approaches to chronic liver diseases including liver cirrhosis and cancer, with particular emphasis on genomics, biostatistics, bioinformatics, clinical diagnostics, and chemical biology, and is currently focusing on the following projects with NIH support.
1. Molecular signature for clinical outcome prediction in liver cirrhosis and cancer.
2. Molecular classification of liver cancer to guide personalized treatment.
3. Nanotechnology-based drug delivery for treatment of liver cirrhosis and cancer.
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto M, Watanabe G, Daidone MG, Roayaie S, Schwartz M, Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. The New England journal of medicine 2008 Nov; 359(19): 1995-2004.
Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson KL, Chung RT, Gould J, Kojima K, Gupta S, Taylor B, Crenshaw A, Gabriel S, Minguez B, Iavarone M, Friedman SL, Colombo M, Llovet JM, Golub TR. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology 2013 May; 144(5): 1024-30.
Hoshida Y, Nijman SM, Kobayashi M, Chan JA, Brunet JP, Chiang DY, Villanueva A, Newell P, Ikeda K, Hashimoto M, Watanabe G, Gabriel S, Friedman SL, Kumada H, Llovet JM, Golub TR. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer research 2009 Sep; 69(18): 7385-92.
Hoshida Y, Fuchs BC, Tanabe KK. Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges [review]. Current cancer drug targets 2012 Nov; 12(9): 1129-59.
Hoshida Y. Molecular epidemiology of hepatocellular carcinoma. Clinical Liver Disease: an official learning resource of American Association for the Study of Liver Diseases 2012 1(6):177-9.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Hoshida did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Hess Center for Science and Medicine; Tisch Cancer Institute
1470 Madison Ave, Box 1123
New York, NY 10029